Physician profile
William Healy
NPI 1992024608
$2,093.56
in general payments reported to CMS, 2019-2025
31 companies · $294 in 2025
The $294 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $715 · 2020: $28.70 · 2021: $83.51 · 2022: $585 · 2023: $136 · 2024: $251 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $466 · Education: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $466.20 |
| Education | $214.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $540.72 | 2021-2025 | Wakix |
| Zoll Respicardia, INC. | $267.09 | 2019 | |
| Jazz Pharmaceuticals INC. | $152.48 | 2019 | |
| Inspire Medical Systems, INC. | $144.12 | 2022 | |
| Abiomed | $125.34 | 2024 | Impella |
| Grifols Shared Services North America, INC. | $115.77 | 2022-2023 | Prolastin-C Liquid |
| Genzyme Corporation | $71.97 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.33 | 2019-2023 | |
| Philips North America LLC | $51.48 | 2019 | |
| Inari Medical, INC. | $50.51 | 2022 | |
| Resmed Corp | $45.36 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $43.96 | 2019-2025 | Fasenra |
| Novartis Pharmaceuticals Corporation | $34.43 | 2019 | |
| Pulmonx Corporation | $33.12 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Axsome Therapeutics, INC. | $33.05 | 2025 | Sunosi |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $31.91 | 2019 | |
| Nonin Medical, INC. | $31.60 | 2025 | Nonin Oximetry |
| Genentech USA, INC. | $31.06 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $29.82 | 2022 | |
| Mylan Specialty L.P. | $28.09 | 2019-2022 | |
| Insmed, INC. | $27.20 | 2019 | |
| United Therapeutics Corporation | $21.80 | 2022 | |
| Shionogi INC | $21.49 | 2025 | Fetroja |
| Xeris Pharmaceuticals, INC. | $20.38 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.68 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.36 | 2020 | |
| Ambu INC. | $13.59 | 2025 | |
| Merck Sharp & Dohme LLC | $12.70 | 2019 | |
| Aurinia Pharma U.S., INC. | $12.12 | 2022 | |
| Shire North American Group INC | $12.03 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Healy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.